Cargando…
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
Acne is a common disorder affecting the majority of adolescents and often extends into adulthood. The central pathophysiological feature of acne is increased androgenic stimulation and/or end-organ sensitivity of pilosebaceous units leading to sebum hypersecretion and infundibular hyperkeratinizatio...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971705/ https://www.ncbi.nlm.nih.gov/pubmed/21072290 |
_version_ | 1782190648639619072 |
---|---|
author | Tan, Jerry KL Ediriweera, Chemanthi |
author_facet | Tan, Jerry KL Ediriweera, Chemanthi |
author_sort | Tan, Jerry KL |
collection | PubMed |
description | Acne is a common disorder affecting the majority of adolescents and often extends into adulthood. The central pathophysiological feature of acne is increased androgenic stimulation and/or end-organ sensitivity of pilosebaceous units leading to sebum hypersecretion and infundibular hyperkeratinization. These events lead to Propionibacterium acnes proliferation and subsequent inflammation. Hormonal therapy, including combined oral contraceptives (OCs), can attenuate the proximate androgenic trigger of this sequence. For many women, hormonal therapy is a rational option for acne treatment as it may be useful across the spectrum of severity. Drospirenone (DRSP) is a unique progestin structurally related to spironolactone with progestogenic, antimineralocorticoid, and antiandrogenic properties. It is available in 2 combined OC preparations (30 μg EE/3 mg DRSP; Yasmin(®) in a 21/7 regimen; and 20 μg EE/3 mg DRSP; Yaz(®) in a 24/4 regimen). These preparations are bereft of the fluid retentional side effects typical of other progestins and their safety has been demonstrated in large epidemiological studies in which no increased risk of vascular thromboembolic disease or arrhythmias was observed. In acne, the efficacy of DRSP-containing OCs has been shown in placebo-controlled superiority trials and in active-comparator non-inferiority trials. |
format | Text |
id | pubmed-2971705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-29717052010-11-10 Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne Tan, Jerry KL Ediriweera, Chemanthi Int J Womens Health Review Acne is a common disorder affecting the majority of adolescents and often extends into adulthood. The central pathophysiological feature of acne is increased androgenic stimulation and/or end-organ sensitivity of pilosebaceous units leading to sebum hypersecretion and infundibular hyperkeratinization. These events lead to Propionibacterium acnes proliferation and subsequent inflammation. Hormonal therapy, including combined oral contraceptives (OCs), can attenuate the proximate androgenic trigger of this sequence. For many women, hormonal therapy is a rational option for acne treatment as it may be useful across the spectrum of severity. Drospirenone (DRSP) is a unique progestin structurally related to spironolactone with progestogenic, antimineralocorticoid, and antiandrogenic properties. It is available in 2 combined OC preparations (30 μg EE/3 mg DRSP; Yasmin(®) in a 21/7 regimen; and 20 μg EE/3 mg DRSP; Yaz(®) in a 24/4 regimen). These preparations are bereft of the fluid retentional side effects typical of other progestins and their safety has been demonstrated in large epidemiological studies in which no increased risk of vascular thromboembolic disease or arrhythmias was observed. In acne, the efficacy of DRSP-containing OCs has been shown in placebo-controlled superiority trials and in active-comparator non-inferiority trials. Dove Medical Press 2010-08-09 /pmc/articles/PMC2971705/ /pubmed/21072290 Text en © 2009 Tan and Ediriweera, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Tan, Jerry KL Ediriweera, Chemanthi Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
title | Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
title_full | Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
title_fullStr | Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
title_full_unstemmed | Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
title_short | Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
title_sort | efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971705/ https://www.ncbi.nlm.nih.gov/pubmed/21072290 |
work_keys_str_mv | AT tanjerrykl efficacyandsafetyofcombinedethinylestradioldrospirenoneoralcontraceptivesinthetreatmentofacne AT ediriweerachemanthi efficacyandsafetyofcombinedethinylestradioldrospirenoneoralcontraceptivesinthetreatmentofacne |